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Strengths and limitations of this study
 ► This study used validated measures of fatigue, rheu-
matoid arthritis (RA) disease activity, pain, sleep and 
psychological distress, and vitamin D status was 
analysed by liquid chromatography–tandem mass 
spectrometry.
 ► The variability in fatigue scores and serum 
25- hydroxyvitamin D was substantial, ensuring ro-
bust correlation and regression analyses.
 ► The sample (n=169) was representative for pa-
tients with established RA; nearly all patients 
received disease- modifying antirheumatic drug 
treatment, and 89% met the 2010 American 
College of Rheumatology/European League Against 
Rheumatism (ACR/EULAR) classification criteria for 
RA when applied retrospectively.
 ► The study was performed at a single centre using a 
sample of convenience.
AbStrACt
Objectives In rheumatoid arthritis (RA), fatigue is an 
important complaint with a significant impact on quality 
of life. Vitamin D has modulatory effects on cells of the 
immune system and may potentially affect RA disease 
activity and thereby RA- related fatigue. The purpose of this 
study was to explore associations between fatigue and 
vitamin D status in patients with RA.
Design Hypothesis- generating cross- sectional study.
Setting Scheduled follow- up visits at a hospital- based 
general rheumatology clinic.
Participants Patients (n=169) with established RA.
Primary outcome measures and anlyses Fatigue, 
assessed by the Chalder fatigue questionnaire, and 
serum concentrations of 25- hydroxyvitamin D (25(OH)
D), assessed by liquid chromatography–tandem mass 
spectrometry. Associations were analysed by correlation, 
and multivariate linear regression with adjustments 
for age, sex, body mass index, RA disease activity as 
measured by the Disease Activity Score 28- joint count C 
reactive protein (DAS28- CRP), psychological distress, pain 
and sleep. Fatigue was also compared across four groups 
based on the levels of serum 25(OH)D with cut points at 
30, 50 and 75 nmol/L using one- way analysis of variance.
results Two- thirds of the patients (116/169, 69%) 
were classified with low RA disease activity, that is, a 
DAS28- CRP score below 3.2. Their mean (SD) serum 
25(OH)D concentration was 56.3 (21.2) nmol/L, with 77 
(45.6%) having values below 50 nmol/L and 12 patients 
(7.1%) below 30 nmol/L. The correlation between fatigue 
and serum concentrations of 25(OH)D was weak and 
not statistically significant, r = −0.14 (95% CI: −0.29 
to 0.03, p=0.08). In the multivariate model, fatigue 
was significantly associated with RA disease activity, 
psychological distress and pain, but not with serum 25(OH)
D. Fatigue did not differ across groups with varying levels 
of serum 25(OH)D.
Conclusion This cross- sectional study found no evidence 
of association between vitamin D and fatigue in patients 
with RA.
bACkgrOunD
In rheumatoid arthritis (RA), fatigue is an 
important complaint with a significant impact 
on quality of life.1 RA patients rank fatigue as 
one of their most disabling symptoms, and 
measures of fatigue provides information 
central to the understanding of the outcome 
of this disease.2 3 The cause of fatigue in RA 
is not well known; studies on the relationship 
with inflammation have yielded inconsistent 
results and many patients continue to expe-
rience fatigue even after achieving remission 
or low disease activity.4 5 In patients with RA, 
as well as in other clinical conditions and in 
the general population, fatigue correlates 
with pain, anxiety, depression, sleep distur-
bance and obesity.6–10
Vitamin D has both direct and indirect 
modulatory effects on cells of the immune 
system.11 It has been hypothesised that 
vitamin D deficiency could contribute to 
increased immune activation, thus playing a 
role in RA pathogenesis.12 Systematic reviews 
have found evidence for a negative associa-
tion between serum vitamin D and RA disease 
activity.13 14 Whether vitamin D status is linked 
to fatigue in RA is unknown.
An established marker for vitamin D status is 
the serum concentration of 25- hydroxyvitamin 
D (25(OH)D), representing both dietary 
and skin- synthetised vitamin D. Currently 
no consensus exists on the optimal level of 
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vitamin D deficiency vary from 30 to 50 nmol/L, whereas 
serum concentrations between 50 and 75 nmol/L have 
been suggested to represent vitamin D insufficiency.15–18 
Of note, 1 nmol/L 25(OH)D corresponds to 0.4 ng/mL.
While vitamin D status in RA patients has been investi-
gated with regard to depression and anxiety,19 studies into 
the potential association with fatigue remain scarce. Since 
effective interventions against fatigue remain elusive, 
there is a need for hypothesis- generating research into 
potential modifiable sources of fatigue in RA. The aim 
of the current study was to explore cross- sectional asso-
ciations between fatigue and vitamin D status in patients 
with RA.
MethODS
Patient and public involvement
Patients or the public were not involved in the design of 
the study.
Patients, setting and procedures
This cross- sectional study took place at the Department of 
Rheumatology, Østfold Hospital Trust, a general rheuma-
tology clinic in south- east Norway responsible for services 
for approximately 300 000 people. Patients were consec-
utively recruited by the hospital staff during scheduled 
follow- up visits to the clinic. Written informed consent 
was obtained from all participants. Inclusion criteria 
were age ≥18 years, a clinical diagnosis of RA and ability 
to read and understand Norwegian. Clinical information 
from history and examination was collected and reported 
by trial care givers (physicians or nurses) at the inclusion 
in the study. The recruitment started in September 2013 
and was completed in June 2015. All data were collected 
at the date of inclusion in the study.
Instruments and assessments
Background and clinical characteristics
Patients provided information on their educational, work 
and smoking status. Years since the diagnosis of RA and 
current disease- modifying antirheumatic drug (DMARD) 
treatment, including oral glucocorticoids, were obtained 
from patients’ medical records.
The 2010 ACR/EULAR classification criteria for RA20 
were retrospectively applied by chart review by an experi-
enced rheumatologist (AJH), using a score of ≥6 to clas-
sify definite RA. RA disease activity was assessed by the 
Disease Activity Score 28- joint count C reactive protein 
(DAS28- CRP) based on the number of swollen and 
tender joints, a visual analogue scale of general health 
and C reactive protein (CRP; mg/L).21 22 The DAS28- CRP 
ranges from 0 to 9.4, scores below 3.2 are considered 
representing low disease activity.23
Body mass index (BMI) was calculated as weight in kilo-
grams divided by height in square metres.
Psychological distress was assessed by the Hospital 
Anxiety and Depression Scale (HADS).24 25 The HADS 
consists of one scale for depression and one for anxiety, 
each comprising seven items which are scored from 0 to 
3. The total score ranges from 0 to 42, higher scores indi-
cate an increased level of symptoms.
Sleep disturbance was assessed by the first dimension of 
the Basic Nordic Sleep Questionnaire26 (‘Have you had 
difficulties falling asleep during the last 3 months’) on a 
five- point Likert scale ranging from 1 (never or less than 
once per month) to 5 (every night or almost daily).
Pain severity was assessed by the average pain last 
24 hours item of the Brief Pain Inventory27 on a numer-
ical rating scale from 0 (no pain) to 10 (pain as bad as you 
can imagine).
Fatigue
Fatigue was assessed by the Chalder fatigue questionnaire 
(CFQ)28 29 The CFQ asks about fatigue symptoms experi-
enced during the last 4 weeks including two scales, phys-
ical fatigue (seven items) and mental fatigue (four items). 
All items are scored on a four- point Likert scale, and the 
sum score produces the total fatigue score ranging from 
0 to 33. Higher scores indicate more fatigue. The CFQ 
has been used to assess fatigue in the Norwegian general 
population and in a variety of clinical settings.30 31
Vitamin D measurement
Serum 25(OH)D refers to the sum of the concentrations 
of the metabolites 25(OH)D2 and 25(OH)D3. Analysis 
with determination of 25(OH)D2/D3 was performed 
consecutively at the Hormone laboratory at the Depart-
ment of Medical Biochemistry, Oslo University Hospital, 
using an in- house liquid chromatography–tandem mass 
spectrometry method. In brief, after protein precipita-
tion, 25(OH)D was extracted from samples using phos-
pholipid depletion plates. Separation was achieved by 
reversed- phase chromatography and the isobaric C3 
epimer 3- epi-25(OH)D3 was separated from 25(OH)
D3. Mass spectrometric detection was performed by 
electrospray ionisation and triple quadruple ion sepa-
ration (multiple reaction monitoring). The laboratory 
participated in the Vitamin D External Quality Assess-
ment Scheme32 for total 25(OH)D is accredited by the 
Norwegian Accreditation as a testing laboratory, and it 
complies with the general requirements for the compe-
tence of testing and calibration laboratories (ISO/IEC 
17025:2017). The total analytical variation, expressed as 
relative SD, was below 13%.
Analysis
Associations between fatigue and vitamin D were anal-
ysed by correlation (Pearson r with bootstrap 95% CI) 
and multivariate linear regression. The multivariate anal-
ysis was performed using total fatigue score as dependent 
variable, and serum 25(OH)D, age, sex, BMI, RA disease 
activity, psychological distress, pain and sleep disturbance 
as independent variables. Assumptions underlying linear 
regression analysis regarding normality and linearity were 
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Table 1 Patient characteristics (n=169)
Females, n (%) 123 (72.8)
Age, years, mean (SD) 58.4 (11.2)
College or university education (≥4 years), n 
(%)
48 (28.4)
Full- time or part- time work, n (%) 51 (30.2)
Current smoker, n (%) 23 (13.6)
Body mass index, mean (SD) 26.4 (4.1)
Years since RA diagnosis, median (IQR) 9 (4.0–17.5)
DAS28- CRP, mean (SD) 2.9 (1.3)




  Synthetic DMARDs only, n (%) 69 (40.8)
  Synthetic and biologic DMARDs, n (%) 60 (35.5)
  Biologic DMARDs only, n (%) 21 (12.4)
  Oral glucocorticoids only, n (%) 5 (3.0)
  None, n (%) 14 (8.3)
Fatigue* (0–33), mean (SD) 15.2 (4.8)
Pain† (0–10), median (IQR) 4 (2–5)
Sleep disturbance‡ (0–5), median (IQR) 2 (2–3)
Psychological distress§ (0–42), median (IQR) 7 (3.75–11.0)
Serum 25(OH)D, nmol/L, mean (SD) 56.3 (21.2)
Serum 25(OH)D
  <30 nmol/L, n (%) 12 (7.1)
  30–49 nmol/L, n (%) 65 (38.5)
  50–74 nmol/L, n (%) 67 (39.6)
  ≥75 nmol/L, n (%) 25 (14.8)
*Chalder fatigue questionnaire.
†Brief Pain Inventory average pain (last 24 hours).
‡Basic Nordic Sleep Questionnaire.
§Hospital Anxiety and Depression Scale.
CRP, C reactive protein; DAS28- CRP, Disease Activity Score 
28- joint count CRP; DMARDs, disease- modifying antirheumatic 
drugs; 25(OH)D, 25- hydroxyvitamin D; RA, rheumatoid arthritis.
In order to investigate potential threshold effects of 
serum 25(OH)D on fatigue, patients were categorised 
into four groups: (1) <30 nmol/L, (2) 30–49 nmol/L, 
(3) 50–74 nmol/L and (4) ≥75 nmol/L. The cut points 
were based on the increased risk of rickets/osteomalacia 
at serum levels below 30 nmol/L, and the uncertainty 
in the literature as to whether 50 nmol/L or 75 nmol/L 
represents safe and sufficient 25(OH)D levels. A one- way 
analysis of variance (ANOVA) was conducted to compare 
fatigue across these groups.
P values <0.05 were considered statistically significant; 
all tests were two- sided. Analyses were performed by IBM 
SPSS Statistics for windows V25.0 (IBM Corp.).
reSultS
In total 208 patients were consecutively invited to partic-
ipate in the study, of whom 178 (86 %) gave written 
informed consent. Six patients were excluded due to 
missing data, and three were excluded due to an incorrect 
RA diagnosis, leaving 169 patients available for analyses.
Clinical and socio- demographic characteristics are 
presented in table 1.
The sample included patients with established disease 
with a median (IQR) disease duration of 9 (4–17.5) years. 
Nearly all patients (155/169, 92%) received synthetic 
and/or a biologic DMARD treatment, and/or oral gluco-
corticoids. Of 22 patients taking oral glucocorticoids, 5 
patients did not receive a DMARD. Two- thirds (116/169, 
69%) were classified with low RA disease activity, that is, a 
DAS28- CRP score below 3.2. In total 89% (149/167) met 
the retrospectively applied 2010 ACR/EULAR classifica-
tion criteria for RA.
Patients’ mean (SD) serum 25(OH)D was 56.3 (21.2) 
nmol/L, with 77 (46%) having a serum 25(OH)D 
concentration below 50 nmol/L and 12 patients (7%) 
having a serum 25(OH)D below 30 nmol/L. The mean 
(SD) fatigue score was 15.2 (4.8).
The correlation between fatigue and serum concentra-
tions of 25(OH)D was weak and not statistically significant, 
r =−0.14 (95% CI: −0.29 to 0.03, p=0.08) (figure 1). In the 
multivariate analysis, fatigue was significantly associated 
with RA disease activity, psychological distress and pain, 
but not with serum 25(OH)D (table 2). Fatigue scores 
did not differ across varying levels of serum 25(OH)D 
(ANOVA; F(3.165)=1.05, p=0.37) (figure 2).
DISCuSSIOn
In this cross- sectional study of patients with established 
RA, fatigue was not associated with vitamin D status. We 
are not aware of other studies of vitamin D and fatigue in 
RA, but the lack of association is consistent with previous 
studies in systemic lupus erythematosus,33 34 inflamma-
tory bowel disease35 and multiple sclerosis.36 A Mendelian 
randomisation study did not find genetic evidence for a 
causal effect of 25(OH)D on fatigue.37 Vitamin D supple-
mentation did not improve fatigue in patients with breast 
cancer38 or chronic fatigue syndrome,39 nor in primary 
care patients with mild to moderate vitamin D defi-
ciency.40 A small effect of supplementation was reported 
in otherwise healthy individuals.41
Our results are in line with a well- established associa-
tion between fatigue and psychological distress.4 They 
also support previous findings of correlation with RA 
disease activity and pain.6 As expected, the mean level 
of fatigue in this cohort was higher than what has been 
reported from general population samples.30 42 43
In this cohort, nearly half of the subjects had serum 
25(OH)D concentrations below 50 nmol/L. Comparing 
our results with other populations or samples is compli-
cated due to varying sun exposure, skin pigmentation, 
ethnicity, vitamin D intake/supplementation and analyt-
ical methodology.44 45 In two samples from the general 
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Figure 1 Relationship between fatigue and serum 25(OH)D. 
25(OH)D, 25- hydroxyvitamin D.




Serum 25(OH)D −0.01 −0.04 to 0.02 0.66
Age −0.03 −0.08 to 0.03 0.31
Sex −0.26 −1.59 to 1.06 0.70
Body mass index 0.03 −0.13 to 0.18 0.74
DAS28- CRP 0.66 0.14 to 1.18 0.01
Psychological distress* 0.32 0.21 to 0.44 <0.001
Pain† 0.47 0.14 to 0.79 0.01
Sleep disturbance‡ 0.11 −0.47 to 0.69 0.71
*Hospital Anxiety and Depression Scale.
†Brief Pain Inventory average pain (last 24 hours).
‡Basic Nordic Sleep Questionnaire.
DAS28- CRP, Disease Activity Score 28- joint count C reactive 
protein; 25(OH)D, 25- hydroxyvitamin D.
Figure 2 Fatigue according to vitamin D levels. Total 
range (whiskers), medians (horizontal lines) and 25%–75% 
IQRs (boxes) of fatigue. Box widths are scaled according to 
counts.
D below 50 nmol/L.44 46 Whether RA patients in general 
have lower levels of 25(OH)D than healthy controls is 
unsettled.13 47
The strengths of this study are the use of validated 
measures of fatigue as well as RA disease activity, pain, sleep 
and psychological distress. Vitamin D status was analysed 
by liquid chromatography–tandem mass spectrometry, a 
method considered reference standard in the measure-
ment of serum 25(OH)D.48 It was performed at a single 
centre using a sample of convenience but we believe that 
the setting was appropriate for the purpose, namely to 
generate hypotheses on the association between vitamin 
D and fatigue in RA. The proportion of patients who met 
the 2010 ACR/EULAR classification criteria for RA (89%) 
was similar to validation studies using diagnosis by a rheu-
matologist as reference standard.49 Socio- demographic 
characteristics, disease activity and drug therapy were 
also very similar to RA patients treated in Norwegian 
rheumatology clinics at that period.50 51 Furthermore, 
the variability in fatigue scores and serum 25(OH)D was 
substantial, ensuring robust correlation analyses. Among 
the limitations of this study are those inherent to cross- 
sectional studies such as unknown temporal sequence 
of associated factors. Our sample included patients with 
established RA and the results do not apply to those with 
very early disease.
In conclusion, this hypothesis- generating cross- sectional 
study found no basis for vitamin D to be associated with 
fatigue in patients with established RA.
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